Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth
NEW YORK, Aug. 30, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0555132/Kidney-and-Renal-Diseases-Therapeutics-Market-to-2017---Strong-Pipeline-and-Unmet-Need-Due-to-Poor-Safety-Profiles-to-Create-Opportunities-for-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Summary
GBI Research's report, "Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth", provides in-depth analysis of unmet needs, drivers and barriers that impact the global kidney and renal diseases therapeutics market. The report analyzes the markets for kidney and renal diseases therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
Scope
The scope of this report includes -
- Annualized market data for the kidney and renal diseases therapeutics market from 2001 to 2010, forecast forward to 2017
- Analysis of the leading therapeutic segments.
- Analysis of the kidney and renal diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
- Market characterization of the kidney and renal diseases therapeutics market including market size, annual cost of therapy, and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies.
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2010 in the global kidney and renal diseases therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
Table of Contents
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 8
2 Kidney and Renal Diseases Therapeutics Market to 2017 - Introduction 11
2.1 GBI Research Report Guidance 12
3 Kidney and Renal Diseases Therapeutics Market to 2017 - Market Overview 13
3.1 Introduction 13
3.2 Revenue Forecasts for the Global Kidney and Renal Disease Market 13
3.2.1 Revenue 13
3.2.2 Annual Cost of Treatment (ACT) 14
3.3 Treatment Usage Patterns 15
3.3.1 Diseased Population 16
3.3.2 Treatment Seeking Population 17
3.3.3 Diagnosis Population 18
3.3.4 Prescription Population 19
4 Kidney and Renal Diseases Therapeutics Market to 2017 - Geographical Landscape 20
4.1 Revenue Analysis by Geography 20
4.2 The US 21
4.2.1 Revenue 21
4.2.2 Annual Cost of Treatment 22
4.3 Top Five Countries of Europe 23
4.3.1 Revenue 23
4.3.2 Annual Cost of Treatment 24
4.4 Japan 25
4.4.1 Revenue 25
4.4.2 Annual Cost of Treatment 26
5 Kidney and Renal Diseases Therapeutics Market to 2017 - Therapeutic Landscape 27
5.1 Chronic Kidney Diseases Market 27
5.1.1 Introduction 27
5.1.2 Revenue 27
5.1.3 Annual Cost of Treatment 30
5.1.4 Treatment Usage Patterns 31
5.1.5 Drivers and Barriers for the Chronic Kidney Diseases Market 36
5.1.6 Drivers for the Chronic Kidney Disease Market 36
5.1.7 Barriers for the Chronic Kidney Disease Market 36
5.2 Renal Anemia Market 37
5.2.1 Introduction 37
5.2.2 Revenue 37
5.2.3 Annual Cost of Treatment 40
5.2.4 Treatment Usage Patterns 41
5.2.5 Drivers and Barriers for the Renal Anemia Market 46
5.2.6 Drivers for the Renal Anemia Market 46
5.2.7 Barriers for the Renal Anemia Market 46
5.3 Diabetic Nephropathy Market 47
5.3.1 Introduction 47
5.3.2 Revenue 47
5.3.3 Annual Cost of Treatment 50
5.3.4 Treatment Usage Patterns 51
5.3.5 Drivers and Barriers for the Diabetic Nephropathy Market 56
5.3.6 Drivers for the Diabetic Nephropathy Market 56
5.3.7 Barriers for the Diabetic Nephropathy Market 56
5.4 Acute Kidney Injury Market 57
5.4.1 Introduction 57
5.4.2 Revenue 58
5.4.3 Annual Cost of Treatment 60
5.4.4 Treatment Usage Patterns 61
5.4.5 Drivers and Barriers for the Acute Kidney Injury Market 66
5.4.6 Drivers for the Acute Kidney Injury Market 66
5.4.7 Barriers for the Acute Kidney Injury Nephropathy Market 66
6 Kidney and Renal Diseases Therapeutics Market to 2017 - Product Pipeline Analysis 67
6.1 Introduction 67
6.1.1 Research and Development Pipeline – Chronic Kidney Disease (CKD) 68
6.1.2 Research and Development Pipeline – Renal Anemia (RA) 74
6.1.3 Research and Development Pipeline – Diabetic Nephropathy (DN) 76
6.1.4 Research and Development Pipeline – Acute Kidney Injury (AKI) 79
6.2 Profiles of Promising Drugs in the Kidney and Renal Disease Market 82
6.2.1 AMG 223 82
6.2.2 AST-120 83
6.2.3 CellCept 84
6.2.4 Ferinject 85
6.2.5 Genz-644470 86
6.2.6 Hematide 87
6.2.7 HEPLISAV 87
6.2.8 Heptar 88
6.2.9 SBR759 89
6.2.10 Sulodexide 90
6.2.11 YM533 90
6.2.12 Zuragen 91
6.2.13 Olmetec 91
7 Kidney and Renal Diseases Therapeutics Market to 2017 - Competitive Landscape 93
7.1 Market Share Analysis 93
7.2 Amgen Inc. 94
7.2.1 Company Overview 94
7.2.2 Business Overview 94
7.2.3 SWOT Analysis 95
7.3 Merck & Co., Inc. 96
7.3.1 Company Overview 96
7.3.2 Business Overview 96
7.3.3 SWOT Analysis 97
7.4 Bristol-Myers Squibb Company 98
7.4.1 Company Overview 98
7.4.2 Business Overview 98
7.4.3 SWOT Analysis 99
7.5 Hoffmann-La Roche Inc. 100
7.5.1 Company Overview 100
7.5.2 Business Overview 100
7.5.3 SWOT Analysis 101
7.6 Shire Inc. 102
7.6.1 Company Overview 102
7.6.2 Business Overview 102
7.6.3 SWOT Analysis 103
8 Kidney and Renal Diseases Therapeutics Market to 2017 - M&A Landscape 104
8.1 M&A Deals 104
8.1.1 Deal Summary 105
8.1.2 Deals by Geography 107
8.2 Licensing Deals 108
8.2.1 Summary of Licensing Deals (2009-2010) 109
8.3 Co-development Deals 111
8.3.1 Summary of Co-development Deals (2009-2010) 112
9 Kidney and Renal Diseases Therapeutics Market to 2017 - Appendix 114
9.1 Market Definitions 114
9.2 Abbreviations 114
9.3 Research Methodology 115
9.3.1 Coverage 115
9.3.2 Secondary Research 116
9.3.3 Primary Research 116
9.3.4 Expert Panel Validation 117
9.4 Contact Us 118
9.5 Disclaimer 118
9.6 Sources 118
List of Tables
1.1 List of Tables
Table 1: Kidney and Renal Diseases Therapeutics Market, Global, Revenue ($bn), 2002-2010 14
Table 2: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 14
Table 3: Kidney and Renal Diseases Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 14
Table 4: Kidney and Renal Diseases Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 14
Table 5: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2010 15
Table 6: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2017 16
Table 7: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 20
Table 8: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 21
Table 9: Kidney and Renal Diseases Therapeutics Market, The US, Revenue ($bn), 2002-2010 21
Table 10: Kidney and Renal Diseases Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2017 22
Table 11: Kidney and Renal Diseases Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2010 22
Table 12: Kidney and Renal Diseases Therapeutics Market, The US, Annual Cost of Treatment ($), 2010-2017 22
Table 13: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002-2010 23
Table 14: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2010-2017 23
Table 15: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 24
Table 16: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 24
Table 17: Kidney and Renal Diseases Therapeutics Market, Japan, Revenue ($bn), 2002-2010 25
Table 18: Kidney and Renal Diseases Therapeutics Market, Japan, Revenue Forecasts ($bn), 2010-2017 25
Table 19: Kidney and Renal Diseases Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010 26
Table 20: Kidney and Renal Diseases Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2017 26
Table 21: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Revenue ($bn), 2002-2010 28
Table 22: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Revenue Forecasts ($bn), 2010-2017 28
Table 23: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Revenue by Geography ($bn), 2002-2010 29
Table 24: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Revenue by Geography ($bn), 2010-2017 29
Table 25: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Annual Cost of Treatment by Geography ($), 2002-2010 30
Table 26: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Annual Cost of Treatment by Geography ($), 2010-2017 30
Table 27: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Treatment Usage Pattern (millions), 2002-2010 31
Table 28: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Treatment Usage Pattern (millions), 2010-2017 32
Table 29: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Revenue ($bn), 2002-2010 38
Table 30: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Revenue Forecasts ($bn), 2010-2017 38
Table 31: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Revenue by Geography ($bn), 2002-2010 39
Table 32: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Revenue by Geography ($bn), 2010-2017 39
Table 33: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Annual Cost of Treatment by Geography ($), 2002-2010 40
Table 34: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Annual Cost of Treatment by Geography ($), 2010-2017 40
Table 35: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Treatment Usage Pattern (millions), 2002-2010 41
Table 36: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Treatment Usage Pattern (millions), 2010-2017 42
Table 37: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Revenue ($bn), 2002-2010 48
Table 38: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Revenue Forecasts ($bn), 2010-2017 48
Table 39: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Revenue by Geography ($bn), 2002-2010 49
Table 40: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Revenue by Geography ($bn), 2010-2017 49
Table 41: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Annual Cost of Treatment by Geography ($), 2002-2010 50
Table 42: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Annual Cost of Treatment by Geography ($), 2010-2017 50
Table 43: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Treatment Usage Pattern (millions), 2002-2010 51
Table 44: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Treatment Usage Pattern (millions), 2010-2017 52
Table 45: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Revenue ($bn), 2002-2010 58
Table 46: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Revenue Forecasts ($bn), 2010-2017 58
Table 47: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Revenue by Geography ($bn), 2002-2010 59
Table 48: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Revenue by Geography ($bn), 2010-2017 59
Table 49: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Annual Cost of Treatment by Geography ($), 2002-2010 60
Table 50: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Annual Cost of Treatment by Geography ($), 2010-2017 60
Table 51: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Treatment Usage Pattern (millions), 2002-2010 61
Table 52: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Treatment Usage Pattern (millions), 2010-2017 62
Table 53: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, R&D Pipeline, 2011 69
Table 54: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, R&D Pipeline, 2011 75
Table 55: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, R&D Pipeline, 2011 77
Table 56: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, R&D Pipeline, 2011 80
Table 57: Kidney and Renal Diseases Therapeutics Market, Global, Major M&A Deals, 2004-2010 104
Table 58: Kidney and Renal Diseases Therapeutics Market, Global, Licensing Deals, 2004-2010 108
Table 59: Kidney and Renal Diseases Therapeutics Market, Global, Major Co-development Deals, 2004-2010 111
List of Figures
1.2 List of Figures
Figure 1: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 13
Figure 2: Kidney and Renal Diseases Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 14
Figure 3: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2017 15
Figure 4: Kidney and Renal Diseases Therapeutics Market, Global, Diseased Population (millions), 2002-2017 16
Figure 5: Kidney and Renal Diseases Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2017 17
Figure 6: Kidney and Renal Diseases Therapeutics Market, Global, Diagnosed Population (millions), 2002-2017 18
Figure 7: Kidney and Renal Diseases Therapeutics Market, Global, Prescription Population (millions), 2002-2017 19
Figure 8: Kidney and Renal Diseases Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 20
Figure 9: Kidney and Renal Diseases Therapeutics Market, The US, Revenue Forecasts ($bn), 2002-2017 21
Figure 10: Kidney and Renal Diseases Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2017 22
Figure 11: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2002-2017 23
Figure 12: Kidney and Renal Diseases Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 24
Figure 13: Kidney and Renal Diseases Therapeutics Market, Japan, Revenue Forecasts ($bn), 2002-2017 25
Figure 14: Kidney and Renal Diseases Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2017 26
Figure 15: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Revenue Forecasts ($bn), 2002-2017 28
Figure 16: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Revenue by Geography ($bn), 2002-2017 29
Figure 17: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Annual Cost of Treatment by Geography ($), 2002-2017 30
Figure 18: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Treatment Usage Pattern (millions), 2002-2017 31
Figure 19: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Diseased Population (millions), 2002-2017 32
Figure 20: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Treatment Seeking Population (millions), 2002-2017 33
Figure 21: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Diagnosed Population (millions), 2002-2017 34
Figure 22: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, Prescription Population (millions), 2002-2017 35
Figure 23: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Diseases, Market Drivers and Barriers, 2010-2017 36
Figure 24: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Revenue Forecasts ($bn), 2002-2017 38
Figure 25: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Revenue by Geography ($bn), 2002-2017 39
Figure 26: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Annual Cost of Treatment by Geography ($), 2002-2017 40
Figure 27: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Treatment Usage Pattern (millions), 2002-2017 41
Figure 28: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Diseased Population (millions), 2002-2017 42
Figure 29: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Treatment Seeking Population (millions), 2002-2017 43
Figure 30: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Diagnosed Population (millions), 2002-2017 44
Figure 31: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Prescription Population (millions), 2002-2017 45
Figure 32: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, Market Drivers and Barriers, 2010-2017 46
Figure 33: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Revenue Forecasts ($bn), 2002-2017 48
Figure 34: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Revenue by Geography ($bn), 2002-2017 49
Figure 35: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Annual Cost of Treatment by Geography ($), 2002-2017 50
Figure 36: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Treatment Usage Pattern (millions), 2002-2017 51
Figure 37: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Diseased Population (millions), 2002-2017 52
Figure 38: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Treatment Seeking Population (millions), 2002-2017 53
Figure 39: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Diagnosed Population (millions), 2002-2017 54
Figure 40: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Prescription Population (millions), 2002-2017 55
Figure 41: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, Market Drivers and Barriers, 2010-2017 56
Figure 42: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Revenue Forecasts ($bn), 2002-2017 58
Figure 43: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Revenue by Geography ($bn), 2002-2017 59
Figure 44: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Annual Cost of Treatment by Geography ($), 2002-2017 60
Figure 45: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Treatment Usage Pattern (millions), 2002-2017 61
Figure 46: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Diseased Population (millions), 2002-2017 62
Figure 47: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Treatment Seeking Population (millions), 2002-2017 63
Figure 48: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Diagnosed Population (millions), 2002-2017 64
Figure 49: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Prescription Population (millions), 2002-2017 65
Figure 50: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, Market Drivers and Barriers, 2010-2017 66
Figure 51: Kidney and Renal Diseases Therapeutics Market, Global, Product Pipeline by Phase (%), 2011 67
Figure 52: Kidney and Renal Diseases Therapeutics Market, Global, Chronic Kidney Disease, R&D Pipeline by Phase, 2011 68
Figure 53: Kidney and Renal Diseases Therapeutics Market, Global, Renal Anemia, R&D Pipeline by Phase, 2011 74
Figure 54: Kidney and Renal Diseases Therapeutics Market, Global, Diabetic Nephropathy, R&D Pipeline by Phase, 2011 76
Figure 55: Kidney and Renal Diseases Therapeutics Market, Global, Acute Kidney Injury, R&D Pipeline by Phase, 2011 79
Figure 56: Kidney and Renal Diseases Therapeutics Market, Global, Top Companies Share, (%), 2009 93
Figure 57: Kidney and Renal Diseases Therapeutics Market, Global, SWOT Analysis of Amgen Inc., 2011 95
Figure 58: Kidney and Renal Diseases Therapeutics Market, Global, SWOT Analysis of Merck & Co., Inc., 2011 97
Figure 59: Kidney and Renal Diseases Therapeutics Market, Global, SWOT Analysis of Bristol-Myers Squibb Company, 2011 99
Figure 60: Kidney and Renal Diseases Therapeutics Market, Global, SWOT Analysis of Roche, 2011 101
Figure 61: Kidney and Renal Diseases Therapeutics Market, Global, SWOT Analysis of Shire, 2011 103
Figure 62: Kidney and Renal Diseases Therapeutics Market, Global, Major M&A Deals by Geography, 2005-2010 107
Figure 63: Kidney and Renal Diseases Therapeutics Market, Global, Major Licensing Deals by Geography, 2005-2010 109
Figure 64: GBI Research Market Forecasting Model 117
Companies Mentioned
Amgen Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Company
Hoffmann-La Roche Inc.
Shire Inc.
To order this report:
Pathology Industry: Kidney and Renal Diseases Therapeutics Market to 2017 - Strong Pipeline and Unmet Need Due to Poor Safety Profiles to Create Opportunities for Growth
Pathology Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article